Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Pyrimidine-thioindole inhibits gastric cancer cell proliferation via up-regulation of expression of tumor suppressor miR-145
Abstract
Purpose: To investigate the effect of pyrimidine-thioindole on gastric cancer proliferation and the underlying mechanism of action.
Methods: Cell viability and apoptosis were determined using MTT assay and Annexin V/PI assay, respectively. Reverse transcription-polymerase chain reaction (RT-PCR) was used for the determination of expression levels of miR-145, while protein expression levels were assayed by western blotting.
Results: Pyrimidine-thioindole treatment significantly inhibited the proliferation of AGS and SNU-5 cells (p < 0.05), but had no effect on the viability of GES-1 cells. Exposure to pyrimidine-thioindole at doses of 8 and 10 µM significantly enhanced the apoptosis of AGS and SNU-5 cells (p < 0.05). Pyrimidinethioindole exposure markedly increased the proportions of AGS and SNU-5 cells in G1 phase (p < 0.05). In AGS and SNU-5 cell lines, pyrimidine-thioindole exposure at doses of 8 and 10 µM significantly upregulated the expression of miR-145, with higher enhancement of miR-145 expression in AGS cells than in SNU-5 cells. Moreover, pyrimidine-thioindole downregulated the expressions of MMP-2, MMP-9, c-Myc, p-PI3K and p-AKT in AGS and SNU-5 cells. Pyrimidine-thioindole treatment enhanced the expression of p21 in AGS and SNU-5 cells, relative to untreated cells (p < 0.05).
Conclusion: These results suggest that pyrimidine-thioindole activates apoptotic signaling pathway, leading to reduction in cell proliferation and arrest of cell cycle. Moreover, it de-activates PI3K/AKT pathway and promotes miR-145 expression in AGS and SNU-5 cells. Thus, pyrimidine-thioindole has therapeutic significance for the management of gastric cancer.
